Downregulated	O
MTAP	B-GP
expression	O
in	O
myxofibrosarcoma	B-DS
:	O
A	O
characterization	O
of	O
inactivating	O
mechanisms	O
,	O
tumor	B-DS
suppressive	O
function	O
,	O
and	O
therapeutic	O
relevance	O

Myxofibrosarcomas	B-DS
are	O
genetically	O
complex	O
and	O
involve	O
recurrently	O
deleted	O
chromosome	O
9p	O
,	O
for	O
which	O
we	O
characterized	O
the	O
pathogenically	O
relevant	O
target	O
(	O
s	O
)	O
using	O
genomic	O
profiling	O
.	O

In	O
12	O
of	O
the	O
15	O
samples	O
,	O
we	O
detected	O
complete	O
or	O
partial	O
losses	O
of	O
9p	O
.	O

The	O
only	O
aggressiveness	O
-	O
associated	O
,	O
differentially	O
lost	O
region	O
was	O
9p21	O
.	O
3	O
,	O
spanning	O
the	O
potential	O
inactivated	O
methylthioadenosine	B-GP
phosphorylase	I-GP
(	O
MTAP	B-GP
)	O
that	O
exhibited	O
homozygous	O
(	O
4	O
/	O
15	O
)	O
or	O
hemizygous	O
(	O
3	O
/	O
15	O
)	O
deletions	O
.	O

In	O
independent	O
samples	O
,	O
MTAP	B-GP
gene	O
status	O
was	O
assessed	O
using	O
quantitative	O
-	O
and	O
methylation	O
-	O
specific	O
PCR	O
assays	O
,	O
and	O
immunoexpression	O
was	O
evaluated	O
.	O

We	O
applied	O
MTAP	B-GP
reexpression	O
or	O
knockdown	O
to	O
elucidate	O
the	O
functional	O
roles	O
of	O
MTAP	B-GP
and	O
the	O
therapeutic	O
potential	O
of	O
L	O
-	O
alanosine	O
in	O
MTAP	B-GP
-	O
preserved	O
and	O
MTAP	B-GP
-	O
deficient	O
myxofibrosarcoma	B-DS
cell	O
lines	O
and	O
xenografts	O
.	O

MTAP	B-GP
protein	O
deficiency	O
(	O
37	O
%)	O
was	O
associated	O
with	O
MTAP	B-GP
gene	O
inactivation	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
by	O
homozygous	O
deletion	O
or	O
promoter	O
methylation	O
,	O
and	O
independently	O
portended	O
unfavorable	O
metastasis	O
-	O
free	O
survival	O
(	O
P	O
=	O
0	O
.	O
0318	O
)	O
and	O
disease	O
-	O
specific	O
survival	O
(	O
P	O
=	O
0	O
.	O
014	O
).	O

Among	O
the	O
MTAP	B-GP
-	O
deficient	O
cases	O
,	O
the	O
homozygous	O
deletion	O
of	O
MTAP	B-GP
predicted	O
adverse	O
outcome	O
.	O

In	O
MTAP	B-GP
-	O
deficient	O
cells	O
,	O
MTAP	B-GP
reexpression	O
inhibited	O
cell	O
migration	O
and	O
invasion	O
,	O
proliferation	O
,	O
and	O
anchorage	O
-	O
independent	O
colony	O
formation	O
and	O
downregulated	O
cyclin	B-GP
D1	I-GP
.	O

This	O
approach	O
also	O
attenuated	O
the	O
tube	O
-	O
forming	O
abilities	O
of	O
human	B-OG
umbilical	O
venous	O
endothelial	O
cells	O
,	O
attributable	O
to	O
the	O
transcriptional	O
repression	O
of	O
MMP	B-GP
-	I-GP
9	I-GP
,	O
and	O
abrogated	O
the	O
susceptibility	O
to	O
L	O
-	O
alanosine	O
.	O

The	O
inhibiting	O
effects	O
of	O
MTAP	B-GP
expression	O
on	O
tumor	B-DS
growth	O
,	O
angiogenesis	O
,	O
and	O
the	O
induction	O
of	O
apoptosis	O
by	O
L	O
-	O
alanosine	O
were	O
validated	O
using	O
MTAP	B-GP
-	O
reexpressing	O
xenografts	O
and	O
reverted	O
using	O
RNA	O
interference	O
in	O
MTAP	B-GP
-	O
preserved	O
cells	O
.	O

In	O
conclusion	O
,	O
homozygous	O
deletion	O
primarily	O
accounts	O
for	O
the	O
adverse	O
prognostic	O
impact	O
of	O
MTAP	B-GP
deficiency	O
and	O
confers	O
the	O
biological	O
aggressiveness	O
and	O
susceptibility	O
to	O
L	O
-	O
alanosine	O
in	O
myxofibrosarcomas	B-DS
.	O

INTRODUCTION	O

Myxofibrosarcoma	B-DS
is	O
characterized	O
by	O
the	O
multinodular	O
growth	O
of	O
spindle	O
to	O
polygonal	O
sarcoma	B-DS
cells	O
within	O
variably	O
myxoid	O
stroma	O
containing	O
long	O
curvilinear	O
vessels	O
[	O
1	O
,	O
2	O
].	O

Clinically	O
,	O
increased	O
tumor	B-DS
grades	O
and	O
stages	O
are	O
frequently	O
observed	O
in	O
myxofibrosarcomas	B-DS
after	O
local	O
recurrence	O
,	O
and	O
may	O
cause	O
metastatic	B-DS
diseases	I-DS
[	O
1	O
–	O
4	O
].	O

However	O
,	O
histological	O
evaluation	O
is	O
insufficiently	O
satisfactory	O
to	O
predict	O
aggressiveness	O
of	O
individual	O
cases	O
,	O
indicating	O
the	O
need	O
to	O
elucidate	O
the	O
pathogenesis	O
of	O
myxofibrosarcoma	B-DS
[	O
2	O
,	O
3	O
].	O

Genetically	O
,	O
complex	O
karyotypic	O
changes	O
are	O
characteristic	O
of	O
myxofibrosarcomas	B-DS
[	O
4	O
,	O
5	O
]	O
and	O
a	O
recent	O
large	O
-	O
scale	O
genomic	O
study	O
indicated	O
that	O
a	O
nonrandom	O
loss	O
of	O
chromosome	O
9	O
,	O
and	O
particularly	O
9p	O
,	O
occurs	O
in	O
myxofibrosarcomas	B-DS
[	O
5	O
].	O

By	O
using	O
ultrahigh	O
-	O
resolution	O
array	O
comparative	O
genomic	O
hybridization	O
(	O
aCGH	O
),	O
we	O
previously	O
profiled	O
the	O
global	O
copy	O
-	O
number	O
alterations	O
(	O
CNAs	O
)	O
in	O
myxofibrosarcoma	B-DS
specimens	O
and	O
cell	O
lines	O
and	O
characterized	O
SKP2	B-GP
on	O
5p	O
and	O
CDK6	B-GP
and	O
MET	B-GP
on	O
7q	O
as	O
amplified	O
oncogenes	B-GP
of	O
pathogenic	O
relevance	O
[	O
6	O
–	O
8	O
].	O

Regarding	O
DNA	O
losses	O
,	O
chromosome	O
9p	O
was	O
the	O
most	O
frequently	O
lost	O
chromosomal	O
arm	O
in	O
myxofibrosarcomas	B-DS
[	O
5	O
],	O
prompting	O
the	O
search	O
for	O
potential	O
tumor	B-GP
suppressor	I-GP
gene	I-GP
(	O
s	O
)	O
underlying	O
this	O
selection	O
pressure	O
for	O
the	O
loss	O
of	O
9p	O
.	O

We	O
characterized	O
methylthioadenosine	B-GP
phosphorylase	I-GP
(	O
MTAP	B-GP
)	O
on	O
9p21	O
.	O
3	O
because	O
whether	O
the	O
tumor	B-DS
-	O
suppressive	O
role	O
of	O
this	O
polyamine	B-GP
metabolism	I-GP
-	I-GP
regulating	I-GP
enzyme	I-GP
is	O
independent	O
from	O
the	O
frequently	O
co	O
-	O
deleted	O
CDKN2A	B-GP
and	O
CDKN2B	B-GP
genes	O
still	O
remains	O
debated	O
[	O
9	O
–	O
12	O
].	O

In	O
this	O
study	O
,	O
MTAP	B-GP
protein	O
deficiency	O
in	O
myxofibrosarcomas	B-DS
was	O
associated	O
with	O
a	O
poor	O
prognosis	O
and	O
inactivated	O
MTAP	B-GP
gene	O
,	O
caused	O
by	O
either	O
homozygous	O
deletion	O
or	O
promoter	O
methylation	O
.	O

Functionally	O
,	O
MTAP	B-GP
deficiency	O
yielded	O
increased	O
aggression	O
in	O
myxofibrosarcoma	B-DS
cells	O
.	O

By	O
restricting	O
the	O
adenosine	O
monophosphate	O
(	O
AMP	O
)	O
supply	O
[	O
13	O
,	O
14	O
],	O
L	O
-	O
alanosine	O
induced	O
prominent	O
apoptosis	O
in	O
the	O
MTAP	B-GP
-	O
deficient	O
myxofibrosarcoma	B-DS
cells	O
and	O
derived	O
xenografts	O
.	O

Collectively	O
,	O
the	O
mechanistic	O
and	O
clinical	O
evidence	O
reinforces	O
MTAP	B-GP
as	O
a	O
functional	O
tumor	B-GP
suppressor	I-GP
gene	I-GP
exhibiting	O
prognostic	O
and	O
therapeutic	O
relevance	O
in	O
myxofibrosarcomas	B-DS
.	O

RESULTS	O

Genomic	O
profiling	O
revealed	O
recurrent	O
9p	O
loss	O

Chromosomal	O
imbalances	O
of	O
varying	O
degrees	O
were	O
detected	O
in	O
all	O
samples	O
subjected	O
to	O
aCGH	O
profiling	O
,	O
indicating	O
more	O
recurrent	O
deletions	O
than	O
gains	O
,	O
and	O
exhibiting	O
characteristically	O
high	O
genomic	O
complexity	O
.	O

According	O
to	O
filter	O
criteria	O
,	O
Nexus	O
software	O
revealed	O
recurrent	O
DNA	O
gains	O
in	O
211	O
chromosomal	O
regions	O
spanning	O
4577	O
genes	O
in	O
all	O
of	O
the	O
genomes	O
.	O

However	O
,	O
235	O
chromosomal	O
regions	O
were	O
nonrandomly	O
lost	O
,	O
involving	O
7871	O
named	O
genes	O
.	O

In	O
the	O
long	O
arm	O
of	O
chromosome	O
9	O
,	O
the	O
copy	O
number	O
alterations	O
were	O
predominantly	O
of	O
DNA	O
gains	O
,	O
except	O
for	O
the	O
9q34	O
region	O
that	O
exhibited	O
DNA	O
losses	O
.	O

In	O
contrast	O
,	O
the	O
complete	O
or	O
partial	O
losses	O
of	O
9p	O
were	O
detected	O
in	O
12	O
of	O
the	O
15	O
samples	O
,	O
and	O
five	O
major	O
deletion	O
cores	O
on	O
9p	O
,	O
recurrent	O
in	O
≥	O
20	O
%	O
of	O
samples	O
tested	O
,	O
were	O
interspersed	O
with	O
short	O
stretches	O
of	O
DNA	O
gains	O
(	O
Figures	O
1A	O
,	O
B	O
,	O
Supplementary	O
Table	O
S1	O
).	O

Within	O
the	O
9p22	O
.	O
2	O
-	O
p21	O
.	O
1	O
deletion	O
core	O
,	O
the	O
sole	O
differentially	O
deleted	O
,	O
aggressiveness	O
-	O
associated	O
region	O
on	O
9p	O
was	O
narrowed	O
down	O
to	O
9p21	O
.	O
3	O
(	O
P	O
=	O
0	O
.	O
0454	O
).	O

This	O
result	O
indicated	O
the	O
implication	O
of	O
9p21	O
.	O
3	O
in	O
the	O
myxofibrosarcoma	B-DS
progression	O
,	O
in	O
which	O
MTAP	B-GP
and	O
CDKN2A	B-GP
/	O
CDKN2B	B-GP
were	O
homozygously	O
deleted	O
in	O
4	O
and	O
4	O
samples	O
and	O
hemizygously	O
deleted	O
in	O
3	O
and	O
3	O
samples	O
,	O
respectively	O
(	O
Table	O
S2	O
).	O

MTAP	B-GP
homozygous	O
deletion	O
in	O
myxofibrosarcoma	B-DS

(	O
A	O
)	O
Referring	O
to	O
chromosome	O
9	O
cytoband	O
,	O
genomic	O
profiling	O
exhibits	O
near	O
arm	O
-	O
level	O
losses	O
of	O
9p	O
clustered	O
in	O
five	O
major	O
deletion	O
cores	O
(	O
top	O
).	O

Within	O
the	O
middle	O
deletion	O
core	O
(	O
9p22	O
.	O
2	O
-	O
p21	O
.	O
1	O
),	O
homozygous	O
deletions	O
frequently	O
involves	O
the	O
aggressiveness	O
-	O
associated	O
9p21	O
.	O
3	O
region	O
as	O
delineated	O
by	O
the	O
rectangle	O
(	O
middle	O
).	O

At	O
higher	O
magnification	O
,	O
the	O
genomic	O
locus	O
of	O
MTAP	B-GP
gene	O
in	O
the	O
9p21	O
.	O
3	O
region	O
is	O
illustrated	O
(	O
bottom	O
).	O

Frequency	O
plots	O
of	O
the	O
CNAs	O
are	O
expressed	O
in	O
blue	O
(	O
gain	O
)	O
or	O
red	O
(	O
loss	O
).	O
(	O
B	O
)	O
The	O
close	O
-	O
up	O
view	O
of	O
representative	O
myxofibrosarcoma	B-DS
cell	O
line	O
(	O
NMFH	O
-	O
2	O
)	O
and	O
tissue	O
(	O
MFS96b	O
)	O
samples	O
shows	O
the	O
homozygous	O
deletion	O
of	O
the	O
MTAP	B-GP
gene	O
.	O

Intratumoral	O
nonneoplastic	O
cells	O
in	O
MFS96b	O
account	O
for	O
the	O
less	O
prominent	O
loss	O
of	O
MTAP	B-GP
copies	O
.	O
(	O
C	O
)	O
Upper	O
:	O
A	O
Grade	O
1	O
myxofibrosarcoma	B-DS
stained	O
with	O
hematoxylin	O
-	O
eosin	O
(	O
left	O
)	O
shows	O
diffused	O
MTAP	B-GP
expression	O
(	O
middle	O
)	O
and	O
a	O
preserved	O
MTAP	B-GP
gene	O
,	O
shown	O
as	O
the	O
red	O
curve	O
in	O
a	O
quantitative	O
DNA	O
-	O
PCR	O
(	O
right	O
).	O

Lower	O
:	O
A	O
Grade	O
3	O
myxofibrosarcoma	B-DS
stained	O
with	O
hematoxylin	O
-	O
eosin	O
(	O
left	O
)	O
shows	O
MTAP	B-GP
-	O
deficient	O
sarcoma	B-DS
cells	O
(	O
middle	O
)	O
and	O
the	O
nondetectable	O
MTAP	B-GP
gene	O
(	O
right	O
).	O

Associations	O
of	O
MTAP	B-GP
immunoexpression	O
with	O
clinicopathological	O
and	O
gene	O
statuses	O
in	O
primary	O
myxofibrosarcomas	B-DS

The	O
MTAP	B-GP
immunostain	O
of	O
87	O
independent	O
primary	O
myxofibrosarcomas	B-DS
(	O
Figure	O
1C	O
)	O
demonstrated	O
an	O
aberrant	O
MTAP	B-GP
deficiency	O
in	O
32	O
cases	O
(	O
37	O
%).	O
MTAP	B-GP
gene	O
dosage	O
was	O
successfully	O
determined	O
in	O
79	O
cases	O
,	O
20	O
of	O
which	O
(	O
25	O
.	O
3	O
%)	O
exhibited	O
homozygous	O
deletion	O
at	O
an	O
MTAP	B-GP
/	O
PFKL	B-GP
ratio	O
of	O
<	O
0	O
.	O
2	O
(	O
Table	O
1	O
,	O
Figure	O
1C	O
).	O

Because	O
13	O
of	O
the	O
29	O
MTAP	B-GP
protein	O
-	O
deficient	O
tumors	B-DS
were	O
not	O
homozygously	O
deleted	O
at	O
the	O
MTAP	B-GP
gene	O
(	O
Table	O
1	O
),	O
methylation	O
-	O
specific	O
PCR	O
was	O
adopted	O
to	O
examine	O
whether	O
promoter	O
hypermethylation	O
alternatively	O
caused	O
protein	O
loss	O
,	O
and	O
10	O
of	O
these	O
13	O
cases	O
were	O
hypermethylated	O
at	O
the	O
MTAP	B-GP
promoter	O
(	O
Table	O
1	O
,	O
Figure	O
S1A	O
).	O

MTAP	B-GP
protein	O
deficiency	O
was	O
strongly	O
related	O
to	O
inactivated	O
MTAP	B-GP
genes	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
Table	O
1	O
),	O
either	O
by	O
homozygous	O
deletion	O
or	O
promoter	O
methylation	O
.	O

Regarding	O
the	O
status	O
of	O
MTAP	B-GP
protein	O
expression	O
and	O
promoter	O
methylation	O
,	O
no	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
clincopathological	O
features	O
,	O
including	O
the	O
tumor	B-DS
grading	O
and	O
staging	O
.	O

By	O
contrast	O
,	O
MTAP	B-GP
homozygous	O
deletion	O
was	O
significantly	O
correlated	O
with	O
high	O
histological	O
grades	O
(	O
P	O
=	O
0	O
.	O
006	O
,	O
Figure	O
1C	O
,	O
Table	O
1	O
)	O
and	O
a	O
high	O
mitotic	O
rate	O
(	O
P	O
=	O
0	O
.	O
011	O
,	O
Figure	O
S1B	O
),	O
and	O
marginally	O
correlated	O
with	O
advanced	O
clinical	O
stages	O
(	O
P	O
=	O
0	O
.	O
097	O
).	O

Associations	O
of	O
clinicopathological	O
features	O
with	O
MTAP	B-GP
immunoexpression	O
and	O
gene	O
status	O
in	O
primary	O
myxofibrosarcomas	B-DS

MTAP	B-GP
Expression	O
(	O
n	O
=	O
87	O
)	O

p	O
-	O
value	O

MTAP	B-GP
Gene	O
(	O
n	O
=	O
79	O
)	O

p	O
-	O
value	O

Deficient	O

Positive	O

HD	O

Non	O
-	O
HD	O

Sex	O

1	O
.	O
000	O

0	O
.	O
936	O

Male	O

18	O

31	O

8	O

23	O

Female	O

14	O

24	O

12	O

36	O

Age	O

1	O
.	O
000	O

0	O
.	O
854	O

<	O
60	O
years	O

12	O

21	O

23	O

7	O

≥	O
60	O
years	O

20	O

30	O

37	O

13	O

Location	O

0	O
.	O
799	O

0	O
.	O
908	O

Extremity	O

23	O

42	O

15	O

45	O

Axial	O

9	O

13	O

5	O

14	O

Tumor	B-DS
necrosis	O

0	O
.	O
483	O

0	O
.	O
115	O

<	O
10	O
%	O

19	O

38	O

41	O

10	O

>=	O
10	O
%	O

13	O

17	O

18	O

10	O

FNCLCC	O
grade	O

0	O
.	O
534	O

0	O
.	O
006	O
*	O

grade	O
1	O

13	O

25	O

30	O

4	O

grade	O
2	O

12	O

23	O

24	O

9	O

grade	O
3	O

7	O

7	O

5	O

7	O

AJCC	O
stage	O

0	O
.	O
763	O

0	O
.	O
097	O

Stage	O
1	O

6	O

14	O

16	O

1	O

Stage	O
2	O

12	O

19	O

21	O

9	O

Stage	O
3	O

13	O

20	O

20	O

10	O

Tumor	B-DS
size	O
&	O

7	O
.	O
314	O
±	O
6	O
.	O
528	O

6	O
.	O
347	O
±	O
3	O
.	O
701	O

0	O
.	O
633	O

6	O
.	O
600	O
4	O
.	O
808	O

7	O
.	O
311	O
5	O
.	O
551	O

0	O
.	O
612	O

Mitotic	O
rate	O
&	O

12	O
.	O
81	O
±	O
13	O
.	O
143	O

10	O
.	O
33	O
±	O
1	O
.	O
695	O

0	O
.	O
585	O

8	O
.	O
780	O
±	O
9	O
.	O
180	O

19	O
.	O
050	O
±	O
15	O
.	O
408	O

0	O
.	O
011	O
*	O

MTAP	B-GP
gene	O
status	O

<	O
0	O
.	O
001	O

Aberration	O
(	O
HD	O
,	O
PM	O
)	O

26	O
(	O
16	O
,	O
10	O
)	O

4	O
(	O
4	O
,	O
0	O
)	O

No	O
aberration	O
(	O
no	O
HD	O
or	O
PM	O
detected	O
)	O

3	O

46	O

HD	O
:	O
homozygous	O
deletion	O
,	O
PM	O
:	O
promoter	O
methylation	O
,	O

:	O
Statistically	O
significant	O
,	O

:	O
t	O
-	O
test	O
,	O

Survival	O
analyses	O

Univariate	O
correlations	O
of	O
the	O
clinical	O
outcome	O
with	O
various	O
clinicopathological	O
,	O
immunohistochemical	O
,	O
and	O
molecular	O
parameters	O
are	O
shown	O
in	O
Table	O
S3	O
and	O
Figure	O
2	O
.	O

MTAP	B-GP
protein	O
deficiency	O
was	O
a	O
significant	O
adverse	O
prognosticator	O
of	O
an	O
adverse	O
DSS	O
(	O
P	O
=	O
0	O
.	O
0195	O
,	O
Figure	O
2A	O
)	O
and	O
was	O
marginally	O
predictive	O
of	O
a	O
short	O
MFS	O
(	O
P	O
=	O
0	O
.	O
0572	O
,	O
Figure	O
2B	O
).	O

Regarding	O
various	O
mechanisms	O
regulating	O
MTAP	B-GP
expression	O
,	O
MTAP	B-GP
-	O
homozygously	O
deleted	O
myxofibrosarcomas	B-DS
behaved	O
aggressively	O
and	O
exhibited	O
significantly	O
shorter	O
DSS	O
(	O
P	O
=	O
0	O
.	O
0129	O
,	O
Figure	O
2C	O
)	O
and	O
MFS	O
(	O
P	O
=	O
0	O
.	O
0150	O
,	O
Figure	O
2D	O
)	O
values	O
than	O
did	O
the	O
cases	O
lacking	O
homozygous	O
deletion	O
.	O

Among	O
the	O
nonhomozygously	O
deleted	O
cases	O
,	O
no	O
difference	O
in	O
prognosis	O
was	O
observed	O
between	O
the	O
MTAP	B-GP
-	O
expressing	O
and	O
MTAP	B-GP
-	O
hypermethylated	O
cases	O
.	O

Compared	O
with	O
the	O
homozygously	O
deleted	O
cases	O
,	O
the	O
MTAP	B-GP
-	O
deficient	O
tumors	B-DS
caused	O
by	O
methylation	O
exhibited	O
a	O
trend	O
toward	O
more	O
favorable	O
outcomes	O
(	O
P	O
=	O
0	O
.	O
0735	O
,	O
Figure	O
2C	O
;	O
P	O
=	O
0	O
.	O
0881	O
,	O
Figure	O
2D	O
).	O

These	O
results	O
suggested	O
variable	O
implications	O
of	O
distinct	O
inactivating	O
mechanisms	O
in	O
MTAP	B-GP
-	O
deficient	O
tumors	B-DS
.	O

In	O
the	O
multivariate	O
analysis	O
(	O
Table	O
S4	O
),	O
MTAP	B-GP
protein	O
deficiency	O
was	O
the	O
single	O
independent	O
prognosticator	O
of	O
an	O
inferior	O
DSS	O
(	O
P	O
=	O
0	O
.	O
0140	O
,	O
hazard	O
ratio	O
=	O
4	O
.	O
020	O
)	O
and	O
,	O
along	O
with	O
high	O
histological	O
grades	O
,	O
could	O
predict	O
inferior	O
MFS	O
(	O
P	O
=	O
0	O
.	O
0318	O
,	O
hazard	O
ratio	O
=	O
2	O
.	O
527	O
).	O

MTAP	B-GP
protein	O
deficiency	O
predicts	O
adverse	O
disease	O
-	O
specific	O

(	O
A	O
)	O
and	O
metastasis	O
-	O
free	O
survival	O
(	O
B	O
)	O
rates	O
.	O

Myxofibrosarcomas	B-DS
involving	O
homozygously	O
deleted	O
MTAP	B-GP
genes	O
yield	O
significantly	O
poor	O
outcomes	O
for	O
both	O
survival	O
endpoints	O
(	O
C	O
,	O
D	O
)	O
and	O
MTAP	B-GP
-	O
expressing	O
and	O
MTAP	B-GP
-	O
methylated	O
cases	O
did	O
not	O
differ	O
prognostically	O
.	O

Tumor	B-DS
suppressive	O
functions	O
of	O
MTAP	B-GP
in	O
myxofibrosarcoma	B-DS

Because	O
of	O
physical	O
proximity	O
,	O
MTAP	B-GP
inactivation	O
by	O
deletion	O
in	O
9p21	O
.	O
3	O
was	O
generally	O
considered	O
a	O
bystander	O
event	O
concomitant	O
with	O
deletions	O
of	O
CDKN2A	B-GP
/	O
B	O
[	O
13	O
,	O
14	O
].	O

Until	O
recently	O
,	O
scholars	O
have	O
started	O
noticing	O
the	O
tumor	B-DS
-	O
suppressive	O
attributes	O
of	O
MTAP	B-GP
that	O
may	O
independently	O
inhibit	O
carcinogenesis	O
[	O
9	O
,	O
11	O
].	O

We	O
first	O
characterized	O
myxofibrosarcoma	B-DS
cell	O
lines	O
regarding	O
their	O
MTAP	B-GP
gene	O
status	O
and	O
endogenous	O
protein	O
expression	O
.	O

Consistent	O
with	O
the	O
aCGH	O
findings	O
,	O
homozygous	O
deletion	O
in	O
OH931	O
and	O
NMFH	O
-	O
2	O
cells	O
was	O
confirmed	O
using	O
real	O
-	O
time	O
PCR	O
quantification	O
without	O
a	O
detectable	O
MTAP	B-GP
DNA	O
copy	O
(	O
Figures	O
3A	O
,	O
S2A	O
),	O
reflective	O
of	O
the	O
absence	O
of	O
MTAP	B-GP
protein	O
expression	O
.	O

Endogenously	O
expressing	O
MTAP	B-GP
,	O
the	O
NMFH	O
-	O
1	O
cells	O
were	O
neither	O
homozygously	O
deleted	O
at	O
the	O
MTAP	B-GP
gene	O
nor	O
methylated	O
at	O
its	O
promoter	O
(	O
Figure	O
3A	O
,	O
S1A	O
).	O

Therefore	O
,	O
we	O
applied	O
MATP	B-GP
-	O
bearing	O
vectors	O
and	O
shMTAP	O
to	O
decipher	O
how	O
inactivated	O
MTAP	B-GP
modulates	O
myxofibrosarcoma	B-DS
phenotypes	O
regarding	O
various	O
cancer	B-DS
hallmarks	O
.	O

The	O
stably	O
transfected	O
and	O
knockdown	O
clones	O
were	O
validated	O
using	O
western	O
blots	O
(	O
Figure	O
3B	O
).	O

In	O
the	O
NMFH	O
-	O
1	O
cells	O
,	O
the	O
silencing	O
of	O
the	O
MTAP	B-GP
transcript	O
with	O
2	O
stable	O
clones	O
of	O
shMTAP	O
was	O
determined	O
using	O
real	O
-	O
time	O
quantitation	O
(	O
Figure	O
S2B	O
).	O

In	O
vitro	O
growth	O
-	O
inhibiting	O
function	O
of	O
MTAP	B-GP
linked	O
to	O
downregulated	O
cyclin	B-GP
D1	I-GP

(	O
A	O
)	O
Compared	O
with	O
reference	O
CCD966SK	O
fibroblasts	O
,	O
the	O
OH931	O
and	O
NMFH	O
-	O
2	O
cell	O
lines	O
were	O
homozygously	O
deleted	O
at	O
the	O
MTAP	B-GP
gene	O
;	O
no	O
DNA	O
copy	O
was	O
detected	O
using	O
real	O
-	O
time	O
PCR	O
(	O
left	O
)	O
and	O
the	O
western	O
blots	O
exhibited	O
no	O
MTAP	B-GP
expression	O
(	O
right	O
).	O

Although	O
the	O
MTAP	B-GP
gene	O
dosage	O
was	O
slightly	O
decreased	O
,	O
a	O
western	O
blotting	O
assay	O
revealed	O
MTAP	B-GP
-	O
expressing	O
NMFH	O
-	O
1	O
cells	O
.	O
(	O
B	O
)	O
Stable	O
exogenous	O
MTAP	B-GP
reexpression	O
was	O
achieved	O
in	O
the	O
OH931	O
(	O
left	O
)	O
and	O
NMFH	O
-	O
2	O
(	O
middle	O
)	O
myxofibrosarcoma	B-DS
cell	O
lines	O
,	O
and	O
the	O
western	O
blots	O
exhibited	O
the	O
expected	O
bands	O
using	O
anti	O
-	O
MTAP	B-GP
.	O

Two	O
clones	O
of	O
shMTAP	O
stably	O
downregulated	O
MTAP	B-GP
expression	O
in	O
NMFH	O
-	O
1	O
cells	O
exhibiting	O
decreased	O
protein	O
abundance	O
(	O
right	O
),	O
compared	O
with	O
the	O
non	O
-	O
targeting	O
shLacZ	O
controls	O
.	O
(	O
C	O
)	O
The	O
BrdU	O
readout	O
,	O
indicating	O
the	O
level	O
of	O
proliferative	O
activity	O
,	O
was	O
significantly	O
reduced	O
in	O
stable	O
MTAP	B-GP
-	O
transfected	O
NMFH	O
-	O
2	O
cells	O
(	O
left	O
),	O
but	O
increased	O
in	O
MTAP	B-GP
-	O
silenced	O
NMFH	O
-	O
1	O
cells	O
(	O
right	O
),	O
compared	O
with	O
the	O
corresponding	O
controls	O
.	O

Depending	O
on	O
the	O
MTAP	B-GP
expression	O
status	O
,	O
only	O
the	O
expression	O
level	O
of	O
cyclin	B-GP
D1	I-GP
in	O
western	O
blots	O
was	O
consistently	O
altered	O
as	O
expected	O
among	O
the	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
cells	O
and	O
2	O
MTAP	B-GP
-	O
knockdown	O
clones	O
of	O
the	O
NMFH	O
-	O
1	O
cells	O
.	O
(	O
D	O
)	O
Compared	O
with	O
the	O
empty	O
controls	O
(	O
left	O
),	O
the	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
transfectants	O
(	O
middle	O
)	O
formed	O
fewer	O
colonies	O
on	O
soft	O
agar	O
,	O
as	O
expressed	O
in	O
the	O
histogram	O
(	O
bottom	O
).	O

MTAP	B-GP
expression	O
inhibited	O
cell	O
proliferation	O
and	O
colony	O
formation	O
of	O
myxofibrosarcoma	B-DS
primarily	O
through	O
the	O
downregulation	O
of	O
cyclin	B-GP
D1	I-GP

To	O
elucidate	O
the	O
potential	O
MTAP	B-GP
-	O
associated	O
antitumor	O
function	O
,	O
we	O
compared	O
the	O
BrdU	O
readout	O
of	O
myxofibrosarcoma	B-DS
cells	O
engineered	O
to	O
manifest	O
various	O
MTAP	B-GP
expression	O
levels	O
.	O

In	O
the	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
myxofibrosarcoma	B-DS
transfectants	O
,	O
the	O
readout	O
indicative	O
of	O
cell	O
proliferation	O
significantly	O
reduced	O
,	O
whereas	O
shMTAP	O
effectively	O
promoted	O
cell	O
proliferation	O
in	O
the	O
NMFH	O
-	O
1	O
cells	O
exhibiting	O
endogenous	O
MTAP	B-GP
(	O
Figure	O
3C	O
).	O

By	O
using	O
an	O
ECIS	O
assay	O
,	O
we	O
measured	O
NMFH	O
-	O
2	O
cells	O
for	O
real	O
-	O
time	O
cell	O
proliferation	O
,	O
revealing	O
a	O
significantly	O
slow	O
cell	O
growth	O
rate	O
in	O
MTAP	B-GP
-	O
reexpressing	O
transfectants	O
(	O
Figure	O
S2C	O
).	O

These	O
observations	O
supported	O
that	O
MTAP	B-GP
may	O
dampen	O
the	O
proliferation	O
of	O
myxofibrosarcoma	B-DS
,	O
prompting	O
investigating	O
whether	O
MTAP	B-GP
expression	O
modulates	O
cell	O
cycle	O
regulators	O
and	O
inhibits	O
colony	O
formation	O
.	O

We	O
performed	O
western	O
blotting	O
to	O
evaluate	O
alterations	O
in	O
the	O
G1	O
-	O
and	O
G1	O
/	O
S	O
-	O
associated	O
cyclins	B-GP
and	O
cyclin	B-GP
-	I-GP
dependent	I-GP
kinases	I-GP
.	O

Among	O
these	O
,	O
only	O
cyclin	B-GP
D1	I-GP
expression	O
was	O
consistently	O
downregulated	O
in	O
both	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
cells	O
and	O
shLac	O
-	O
transfected	O
NMFH	O
-	O
1	O
cells	O
(	O
Figure	O
3C	O
).	O

However	O
,	O
the	O
trend	O
in	O
alterations	O
in	O
cyclin	B-GP
E	I-GP
and	O
CDK2	B-GP
expression	O
varied	O
between	O
exogenous	O
expression	O
and	O
RNA	O
interference	O
approaches	O
as	O
well	O
as	O
between	O
2	O
shMTAP	O
clones	O
.	O

In	O
the	O
flow	O
cytometric	O
analysis	O
,	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
cells	O
exhibited	O
significant	O
cell	O
cycle	O
arrest	O
in	O
the	O
G1	O
phase	O
and	O
concomitant	O
low	O
percentages	O
of	O
cells	O
in	O
the	O
S	O
and	O
G2	O
phases	O
(	O
Figure	O
S2D	O
).	O

In	O
a	O
soft	O
-	O
agar	O
assay	O
,	O
significantly	O
small	O
and	O
few	O
cell	O
colonies	O
were	O
observed	O
in	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
transfectants	O
,	O
substantiating	O
the	O
inhibition	O
of	O
MTAP	B-GP
in	O
anchorage	O
-	O
independent	O
growth	O
(	O
Figure	O
3D	O
).	O

These	O
findings	O
imply	O
that	O
cyclin	B-GP
D1	I-GP
represents	O
the	O
predominant	O
cell	O
cycle	O
regulator	O
associated	O
with	O
the	O
antiproliferative	O
role	O
of	O
MTAP	B-GP
.	O

MTAP	B-GP
expression	O
inhibited	O
cell	O
migration	O
and	O
invasion	O

The	O
results	O
of	O
wound	O
-	O
healing	O
assays	O
indicated	O
significantly	O
rapid	O
wound	O
closure	O
in	O
both	O
NMFH	O
-	O
2	O
cells	O
transfected	O
with	O
an	O
empty	O
vector	O
and	O
NMFH	O
-	O
1	O
cells	O
silenced	O
against	O
endogenous	O
MTAP	B-GP
(	O
Figure	O
S3A	O
,	O
C	O
).	O

According	O
to	O
matrigel	O
invasion	O
assays	O
,	O
the	O
2	O
conditions	O
also	O
yielded	O
significantly	O
increased	O
invading	O
tumor	B-DS
cells	O
(	O
Figure	O
S3B	O
),	O
indicating	O
enhanced	O
metastatic	O
propensity	O
by	O
MTAP	B-GP
deficiency	O
in	O
myxofibrosarcomas	B-DS
.	O

MTAP	B-GP
expression	O
conferred	O
antiangiogenic	O
function	O

Recently	O
,	O
we	O
reported	O
that	O
aberrant	O
loss	O
of	O
argininosuccinate	B-GP
synthetase	I-GP
(	O
ASS1	B-GP
)	O
caused	O
by	O
promoter	O
methylation	O
may	O
contribute	O
to	O
the	O
enhanced	O
angiogenesis	O
in	O
myxofibrosarcomas	B-DS
[	O
15	O
].	O

Because	O
MTAP	B-GP
is	O
linked	O
to	O
polyamine	O
metabolism	O
and	O
adenine	O
and	O
methionine	O
salvage	O
[	O
16	O
,	O
17	O
],	O
examining	O
whether	O
MTAP	B-GP
inactivation	O
promotes	O
angiogenesis	O
by	O
perturbing	O
the	O
metabolic	O
balance	O
of	O
sarcoma	B-DS
cells	O
is	O
conceivable	O
,	O
similar	O
to	O
the	O
scenario	O
involved	O
in	O
deregulated	O
ASS1	B-GP
.	O

Under	O
various	O
experimental	O
conditions	O
used	O
to	O
manipulate	O
MTAP	B-GP
expression	O
,	O
3	O
myxofibrosarcoma	B-DS
cell	O
lines	O
were	O
assessed	O
for	O
the	O
formation	O
of	O
HUVEC	O
tubes	O
incubated	O
with	O
corresponding	O
conditioned	O
media	O
.	O

Using	O
HUVEC	O
assays	O
,	O
the	O
angiogenic	O
capability	O
significantly	O
decreased	O
to	O
55	O
%	O
and	O
60	O
%	O
in	O
the	O
MTAP	B-GP
-	O
reexpressing	O
OH931	O
and	O
NMFH	O
-	O
2	O
transfectants	O
,	O
respectively	O
,	O
but	O
significantly	O
increased	O
up	O
to	O
2	O
~	O
3	O
-	O
fold	O
in	O
the	O
MTAP	B-GP
-	O
silenced	O
NMFH	O
-	O
1	O
cells	O
(	O
Figure	O
4A	O
).	O

Because	O
of	O
increased	O
angiogenesis	O
in	O
the	O
MTAP	B-GP
-	O
deficient	O
state	O
,	O
we	O
used	O
an	O
RT	O
-	O
PCR	O
expression	O
array	O
to	O
explore	O
the	O
potential	O
mediators	O
relevant	O
to	O
MTAP	B-GP
-	O
regulated	O
angiogenesis	O
.	O

Lacking	O
upregulated	O
genes	O
in	O
this	O
angiogenesis	O
-	O
associated	O
panel	O
,	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
cells	O
showed	O
significantly	O
reduced	O
mRNA	O
expression	O
of	O
6	O
candidates	O
(	O
Table	O
S5	O
).	O

Of	O
these	O
,	O
CXCL	B-GP
-	I-GP
9	I-GP
,	O
CXCL	B-GP
-	I-GP
10	I-GP
,	O
and	O
MMP	B-GP
-	I-GP
9	I-GP
proteins	O
were	O
concomitantly	O
downregulated	O
using	O
western	O
blots	O
in	O
both	O
NMFH	O
-	O
2	O
and	O
OH931	O
MTAP	B-GP
-	O
reexpressing	O
cell	O
lines	O
,	O
the	O
conditioned	O
media	O
of	O
which	O
also	O
consistently	O
demonstrated	O
decreased	O
MMP	B-GP
-	I-GP
9	I-GP
protein	O
concentration	O
using	O
ELISA	O
(	O
Figure	O
4B	O
).	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
showed	O
decreased	O
expression	O
of	O
MMP	B-GP
-	I-GP
9	I-GP
mRNA	O
in	O
both	O
MTAP	B-GP
-	O
reexpressing	O
myxofibrosarcoma	B-DS
cell	O
lines	O
(	O
Figure	O
4C	O
).	O

In	O
the	O
MTAP	B-GP
-	O
silenced	O
NMFH	O
-	O
1	O
cells	O
used	O
for	O
cross	O
-	O
validation	O
,	O
MMP	B-GP
-	I-GP
9	I-GP
was	O
the	O
only	O
molecule	O
that	O
exhibited	O
upregulated	O
mRNA	O
and	O
protein	O
expression	O
(	O
Figure	O
4B	O
,	O
C	O
).	O

The	O
luciferase	B-GP
activity	O
of	O
MMP	B-GP
-	I-GP
9	I-GP
promoter	O
significantly	O
reduced	O
in	O
the	O
MTAP	B-GP
-	O
reexpressing	O
OH931	O
and	O
NMFH	O
-	O
2	O
cells	O
(	O
Figure	O
4D	O
).	O

These	O
data	O
demonstrated	O
that	O
MTAP	B-GP
deficiency	O
enhanced	O
the	O
transcriptional	O
upregulation	O
of	O
MMP	B-GP
-	I-GP
9	I-GP
to	O
promote	O
angiogenesis	O
in	O
myxofibrosarcomas	B-DS
.	O

MTAP	B-GP
governs	O
tumor	B-DS
angiogenesis	O
by	O
the	O
transcriptional	O
repression	O
of	O
MMP	B-GP
-	I-GP
9	I-GP

(	O
A	O
)	O
The	O
well	O
-	O
formed	O
HUVEC	O
tubes	O
decrease	O
when	O
exposed	O
to	O
conditioned	O
media	O
from	O
MTAP	B-GP
-	O
reexpressing	O
transfectants	O
of	O
NMFH	O
-	O
2	O
and	O
OH931	O
cells	O
.	O

Conversely	O
,	O
MTAP	B-GP
knockdown	O
promoted	O
angiogenesis	O
in	O
both	O
shMTAP	O
-	O
transduced	O
clones	O
of	O
the	O
NMFH	O
-	O
1	O
cells	O
(	O
left	O
).	O

The	O
relative	O
level	O
of	O
angiogenic	O
tube	O
-	O
forming	O
activity	O
is	O
expressed	O
in	O
the	O
histograms	O
(	O
right	O
).	O
(	O
B	O
)	O
Of	O
the	O
differentially	O
expressed	O
genes	O
identified	O
from	O
the	O
RT	O
-	O
PCR	O
expression	O
array	O
,	O
western	O
blotting	O
validation	O
for	O
both	O
MTAP	B-GP
-	O
reexpressing	O
transfectants	O
exhibited	O
correspondingly	O
decreased	O
protein	O
expression	O
of	O
CXCL	B-GP
-	I-GP
9	I-GP
,	O
CXCL	B-GP
-	I-GP
10	I-GP
,	O
and	O
MMP	B-GP
-	I-GP
9	I-GP
(	O
left	O
).	O

The	O
MMP	B-GP
-	I-GP
9	I-GP
protein	O
concentration	O
secreted	O
into	O
the	O
conditioned	O
media	O
was	O
significantly	O
reduced	O
in	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
and	O
OH931	O
cell	O
lines	O
(	O
middle	O
).	O

Only	O
the	O
level	O
of	O
MMP	B-GP
-	I-GP
9	I-GP
protein	O
expression	O
was	O
significantly	O
upregulated	O
in	O
the	O
cross	O
-	O
validation	O
of	O
MTAP	B-GP
-	O
silenced	O
NMFH	O
-	O
1	O
cells	O
(	O
right	O
).	O
(	O
C	O
)	O
As	O
a	O
representative	O
potential	O
downstream	O
mediator	O
of	O
MTAP	B-GP
,	O
the	O
MMP	B-GP
-	I-GP
9	I-GP
mRNA	O
expression	O
levels	O
were	O
significantly	O
downregulated	O
in	O
the	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
and	O
OH931	O
cells	O
(	O
left	O
)	O
but	O
elevated	O
by	O
MTAP	B-GP
knockdown	O
using	O
quantitative	O
RT	O
-	O
PCR	O
(	O
right	O
).	O
(	O
D	O
)	O
Luciferase	B-GP
activity	O
of	O
MMP	B-GP
-	I-GP
9	I-GP
promoter	O
construct	O
was	O
significantly	O
lower	O
in	O
the	O
NMFH	O
-	O
2	O
and	O
OH931	O
cells	O
transfected	O
with	O
the	O
MTAP	B-GP
-	O
expressing	O
vector	O
than	O
in	O
the	O
empty	O
controls	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
,	O
and	O
the	O
results	O
are	O
expressed	O
as	O
mean	O
±	O
SD	O
.	O

MTAP	B-GP
reexpression	O
inhibited	O
growth	O
of	O
xenografted	O
tumors	B-DS

The	O
in	O
vivo	O
inhibitory	O
effect	O
of	O
MTAP	B-GP
on	O
tumor	B-DS
growth	O
was	O
analyzed	O
in	O
NMFH	O
-	O
2	O
xenografts	O
exhibiting	O
ectopic	O
MTAP	B-GP
reexpression	O
versus	O
empty	O
controls	O
(	O
Figure	O
5A	O
).	O

The	O
xenografts	O
reexpressing	O
MTAP	B-GP
exhibited	O
a	O
significantly	O
small	O
average	O
tumor	B-DS
volume	O
from	O
Day	O
7	O
until	O
sacrifice	O
on	O
Day	O
30	O
,	O
on	O
which	O
the	O
excised	O
specimens	O
were	O
evidently	O
larger	O
and	O
heavier	O
in	O
the	O
controls	O
than	O
were	O
those	O
in	O
the	O
MTAP	B-GP
-	O
reexpressing	O
group	O
.	O

The	O
control	O
xenografts	O
exhibited	O
more	O
high	O
-	O
grade	O
pleomorphic	O
cells	O
in	O
a	O
fibromyxoid	O
matrix	O
and	O
a	O
higher	O
mitotic	O
rate	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
the	O
MTAP	B-GP
-	O
reexpressing	O
xenografts	O
primarily	O
composed	O
of	O
low	O
-	O
grade	O
spindle	O
cells	O
.	O

Immunohistochemically	O
,	O
MTAP	B-GP
-	O
reexpressing	O
xenografts	O
exhibited	O
a	O
significantly	O
reduced	O
labeling	O
of	O
cyclin	B-GP
D1	I-GP
,	O
cyclin	B-GP
E	I-GP
,	O
and	O
Ki	B-GP
-	I-GP
67	I-GP
,	O
as	O
well	O
as	O
decreased	O
intratumoral	O
vessels	O
stained	O
with	O
the	O
CD31	B-GP
endothelial	O
marker	O
,	O
substantiating	O
the	O
antiproliferative	O
and	O
antiangiogenic	O
attributes	O
of	O
MTAP	B-GP
in	O
vivo	O
.	O

In	O
vivo	O
tumor	B-DS
suppressive	O
function	O
of	O
MTAP	B-GP
and	O
the	O
inhibition	O
of	O
L	O
-	O
alanosine	O
in	O
MTAP	B-GP
-	O
deficient	O
myxofibrosarcoma	B-DS

(	O
A	O
)	O
The	O
average	O
tumor	B-DS
volume	O
of	O
the	O
empty	O
vector	O
-	O
transfected	O
NMFH	O
-	O
2	O
xenografts	O
was	O
significantly	O
larger	O
than	O
that	O
of	O
the	O
MTAP	B-GP
-	O
reexpressing	O
counterparts	O
(	O
left	O
).	O

On	O
Day	O
30	O
,	O
the	O
excised	O
xenografts	O
were	O
grossly	O
larger	O
and	O
heavier	O
in	O
the	O
control	O
group	O
than	O
in	O
the	O
MTAP	B-GP
-	O
reexpressing	O
group	O
(	O
middle	O
).	O

Histologically	O
,	O
control	O
xenografts	O
(	O
upper	O
panel	O
)	O
comprise	O
MTAP	B-GP
-	O
deficient	O
high	O
-	O
grade	O
pleomorphic	O
sarcoma	B-DS
cells	O
that	O
exhibit	O
frequent	O
mitotic	O
figures	O
,	O
the	O
increased	O
expression	O
of	O
cyclin	B-GP
D1	I-GP
,	O
cyclin	B-GP
E	I-GP
,	O
Ki	B-GP
-	I-GP
67	I-GP
,	O
and	O
MMP	B-GP
-	I-GP
9	I-GP
,	O
and	O
an	O
increased	O
microvascular	O
density	O
based	O
on	O
CD31	B-GP
staining	O
.	O

However	O
,	O
contrasting	O
results	O
were	O
observed	O
in	O
the	O
MTAP	B-GP
-	O
reexpressing	O
group	O
(	O
lower	O
panel	O
),	O
which	O
exhibited	O
low	O
-	O
grade	O
MTAP	B-GP
-	O
expressing	O
spindle	O
cells	O
(	O
right	O
).	O
(	O
B	O
)	O
L	O
-	O
alanosine	O
effectively	O
attenuated	O
the	O
viability	O
of	O
MTAP	B-GP
-	O
deficient	O
NMFH	O
-	O
2	O
and	O
OH931	O
myxofibrosarcoma	B-DS
cell	O
lines	O
,	O
and	O
MTAP	B-GP
-	O
expressing	O
NMFH	O
-	O
1	O
cells	O
were	O
relatively	O
resistant	O
to	O
L	O
-	O
alanosine	O
,	O
demonstrating	O
>	O
50	O
%	O
viable	O
sarcoma	B-DS
cells	O
,	O
even	O
at	O
100	O
μM	O
(	O
left	O
).	O

Unlike	O
the	O
sensitivity	O
in	O
the	O
parent	O
lines	O
and	O
empty	O
controls	O
,	O
MTAP	B-GP
reexpression	O
caused	O
decreased	O
susceptibility	O
to	O
L	O
-	O
alanosine	O
in	O
the	O
OH931	O
(	O
middle	O
)	O
and	O
NMFH	O
-	O
2	O
(	O
right	O
)	O
cells	O
.	O
(	O
C	O
)	O
The	O
average	O
tumor	B-DS
volume	O
was	O
significantly	O
larger	O
in	O
the	O
PBS	O
-	O
treated	O
group	O
than	O
in	O
the	O
groups	O
treated	O
with	O
25	O
μM	O
and	O
50	O
μM	O
of	O
L	O
-	O
alanosine	O
(	O
left	O
).	O

On	O
Day	O
42	O
,	O
the	O
excised	O
xenografts	O
remained	O
macroscopically	O
larger	O
and	O
heavier	O
in	O
the	O
control	O
group	O
,	O
exhibiting	O
no	O
dose	O
-	O
dependent	O
difference	O
between	O
the	O
groups	O
treated	O
with	O
25	O
μM	O
and	O
50	O
μM	O
of	O
L	O
-	O
alanosine	O
(	O
middle	O
).	O

In	O
contrast	O
to	O
the	O
high	O
-	O
grade	O
pleomorphic	O
histology	O
in	O
the	O
control	O
xenografts	O
lacking	O
apparent	O
apoptosis	O
,	O
the	O
L	O
-	O
alanosine	O
-	O
treated	O
group	O
exhibited	O
increased	O
numbers	O
of	O
fibrohyaline	O
collagen	B-GP
fibers	O
and	O
TUNEL	B-GP
-	O
labeled	O
apoptotic	O
cells	O
(	O
right	O
).	O

MTAP	B-GP
protein	O
deficiency	O
was	O
associated	O
with	O
increases	O
of	O
proliferative	O
index	O
,	O
microvessel	O
density	O
,	O
and	O
MMP	B-GP
-	I-GP
9	I-GP
expression	O
level	O
in	O
primary	O
myxofibrosarcomas	B-DS

In	O
a	O
subset	O
common	O
cohort	O
of	O
40	O
primary	O
myxofibrosarcomas	B-DS
yielding	O
informative	O
scoring	O
results	O
(	O
Table	O
S6	O
,	O
Figure	O
S4	O
),	O
we	O
further	O
corroborated	O
the	O
in	O
vitro	O
findings	O
in	O
clinical	O
samples	O
that	O
MTAP	B-GP
protein	O
deficiency	O
was	O
highly	O
associated	O
with	O
increased	O
Ki	B-GP
-	I-GP
67	I-GP
labeling	O
index	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
microvessel	O
density	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
assessed	O
by	O
CD31	B-GP
staining	O
[	O
18	O
],	O
and	O
MMP	B-GP
-	I-GP
9	I-GP
expression	O
levels	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
evaluated	O
by	O
H	O
-	O
score	O
method	O
[	O
19	O
].	O

L	O
-	O
alanosine	O
inhibited	O
MTAP	B-GP
-	O
deficient	O
myxofibrosarcoma	B-DS
cells	O
and	O
xenografts	O
by	O
inducing	O
apoptosis	O

Because	O
L	O
-	O
alanosine	O
can	O
completely	O
abrogate	O
AMP	O
supply	O
in	O
MTAP	B-GP
-	O
deficient	O
cells	O
,	O
we	O
investigated	O
whether	O
L	O
-	O
alanosine	O
can	O
effectively	O
inhibit	O
this	O
aggressive	O
subset	O
of	O
myxofibrosarcomas	B-DS
by	O
targeting	O
the	O
methionine	O
de	O
novo	O
pathway	O
[	O
13	O
].	O

All	O
myxofibrosarcoma	B-DS
cell	O
lines	O
were	O
incubated	O
with	O
indicated	O
doses	O
of	O
L	O
-	O
alanosine	O
for	O
72	O
h	O
;	O
this	O
attenuated	O
the	O
cell	O
viability	O
in	O
only	O
the	O
MTAP	B-GP
-	O
deficient	O
parent	O
NMFH	O
-	O
2	O
and	O
OH931	O
cells	O
yielding	O
IC50	O
values	O
of	O
approximately	O
1	O
μM	O
and	O
5	O
μM	O
,	O
respectively	O
,	O
but	O
not	O
in	O
the	O
MTAP	B-GP
-	O
expressing	O
NMFH	O
-	O
1	O
cells	O
(	O
Figure	O
5B	O
).	O

Flow	O
cytometry	O
demonstrated	O
a	O
significantly	O
increased	O
sub	O
-	O
G1	O
population	O
in	O
both	O
L	O
-	O
alanosine	O
-	O
treated	O
OH931	O
and	O
NMFH	O
-	O
2	O
cells	O
,	O
and	O
the	O
induction	O
of	O
apoptosis	O
,	O
particularly	O
prominent	O
in	O
the	O
NMFH	O
-	O
2	O
cells	O
,	O
was	O
validated	O
using	O
annexin	B-GP
V	I-GP
/	O
propidium	O
iodide	O
staining	O
assays	O
(	O
Figure	O
S5	O
).	O

Stable	O
MTAP	B-GP
-	O
reexpressing	O
OH931	O
and	O
NMFH	O
-	O
2	O
cells	O
were	O
employed	O
to	O
explore	O
how	O
MTAP	B-GP
expression	O
affected	O
the	O
susceptibility	O
of	O
myxofibrosarcoma	B-DS
cells	O
to	O
L	O
-	O
alanosine	O
(	O
Figure	O
5B	O
).	O

This	O
approach	O
significantly	O
reverted	O
the	O
attenuated	O
cell	O
viability	O
caused	O
by	O
L	O
-	O
alanosine	O
,	O
indicating	O
that	O
its	O
antitumor	O
selectivity	O
was	O
attributable	O
to	O
the	O
MTAP	B-GP
deficiency	O
in	O
myxofibrosarcoma	B-DS
cells	O
.	O

We	O
evaluated	O
the	O
in	O
vivo	O
efficacy	O
of	O
L	O
-	O
alanosine	O
in	O
NMFH	O
-	O
2	O
xenografts	O
(	O
Figure	O
5C	O
).	O

From	O
Day	O
25	O
posttreatment	O
until	O
Day	O
42	O
at	O
sacrifice	O
,	O
significantly	O
smaller	O
tumor	B-DS
volumes	O
were	O
observed	O
in	O
both	O
groups	O
treated	O
with	O
L	O
-	O
alanosine	O
at	O
25	O
μM	O
or	O
50	O
μM	O
,	O
compared	O
with	O
the	O
PBS	O
controls	O
.	O

However	O
,	O
no	O
dose	O
-	O
dependent	O
therapeutic	O
effect	O
was	O
observed	O
.	O

The	O
control	O
xenografts	O
exhibited	O
high	O
-	O
grade	O
pleomorphic	O
histology	O
characterized	O
by	O
frequent	O
atypical	O
mitoses	O
,	O
whereas	O
the	O
L	O
-	O
alanosine	O
-	O
treated	O
specimens	O
exhibited	O
quiescent	O
or	O
apoptotic	O
-	O
appearing	O
cells	O
in	O
a	O
fibromyxoid	O
backdrop	O
containing	O
increased	O
hyaline	O
collagenous	O
fibers	O
.	O

In	O
the	O
L	O
-	O
alanosine	O
-	O
treated	O
xenografts	O
,	O
significantly	O
increased	O
TUNEL	B-GP
-	O
labeled	O
apoptotic	O
cells	O
were	O
observed	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
substantiating	O
the	O
in	O
vivo	O
apoptosis	O
-	O
inducing	O
effect	O
of	O
L	O
-	O
alanosine	O
.	O

DISCUSSION	O

Myxofibrosarcoma	B-DS
is	O
a	O
common	O
,	O
and	O
genetically	O
complex	O
sarcoma	B-DS
of	O
histological	O
and	O
biological	O
heterogeneity	O
,	O
and	O
its	O
therapeutic	O
mainstay	O
is	O
conducting	O
radical	O
surgery	O
to	O
achieve	O
clear	O
margins	O
[	O
2	O
,	O
3	O
].	O

The	O
lack	O
of	O
effective	O
molecular	O
markers	O
and	O
standardized	O
chemoradiotherapeutic	O
regimen	O
(	O
s	O
)	O
dictates	O
an	O
unfavorable	O
prognosis	O
in	O
primary	O
advanced	O
and	O
recurrent	O
myxofibrosarcomas	B-DS
[	O
2	O
,	O
3	O
].	O

By	O
integrating	O
various	O
methodologies	O
,	O
we	O
identified	O
the	O
clinical	O
,	O
biological	O
,	O
and	O
therapeutic	O
relevance	O
of	O
MTAP	B-GP
deficiency	O
,	O
which	O
was	O
observed	O
in	O
37	O
%	O
of	O
primary	O
myxofibrosarcomas	B-DS
,	O
strongly	O
linked	O
to	O
homozygous	O
deletion	O
or	O
promoter	O
methylation	O
,	O
and	O
independently	O
predictive	O
of	O
adverse	O
survival	O
.	O

However	O
,	O
no	O
inactivating	O
mechanism	O
was	O
detected	O
in	O
the	O
3	O
MTAP	B-GP
-	O
deficient	O
cases	O
,	O
suggesting	O
that	O
MTAP	B-GP
downregulation	O
was	O
caused	O
by	O
alternative	O
molecular	O
defects	O
such	O
as	O
small	O
deletions	O
of	O
5	O
′	O
regions	O
[	O
20	O
,	O
21	O
].	O

On	O
the	O
other	O
hand	O
,	O
homozygous	O
deletion	O
of	O
MTAP	B-GP
gene	O
was	O
detected	O
in	O
four	O
cases	O
interpreted	O
as	O
MTAP	B-GP
-	O
expressing	O
.	O

This	O
conflicting	O
finding	O
was	O
most	O
likely	O
attributable	O
to	O
the	O
existence	O
of	O
intratumoral	O
heterogeneity	O
.	O

Whatever	O
whole	O
-	O
block	O
or	O
tissue	O
microarray	O
sections	O
,	O
the	O
MTAP	B-GP
-	O
positive	O
tumor	B-DS
cells	O
only	O
ranged	O
from	O
10	O
%	O
to	O
20	O
%	O
at	O
most	O
,	O
which	O
might	O
not	O
be	O
isolated	O
in	O
the	O
process	O
of	O
laser	O
capture	O
microdissection	O
and	O
therefore	O
result	O
in	O
an	O
underestimated	O
gene	O
ratio	O
skewed	O
toward	O
homozygous	O
deletion	O
.	O

Compared	O
with	O
the	O
equally	O
indolent	O
MTAP	B-GP
-	O
hypermethylated	O
and	O
MTAP	B-GP
-	O
expressing	O
myxofibrosarcomas	B-DS
,	O
MTAP	B-GP
-	O
homozygously	O
deleted	O
tumors	B-DS
were	O
often	O
high	O
-	O
grade	O
and	O
clinically	O
aggressive	O
.	O

This	O
variation	O
in	O
the	O
prognostic	O
effect	O
of	O
MTAP	B-GP
gene	O
abrogation	O
between	O
distinct	O
mechanisms	O
in	O
myxofibrosarcoma	B-DS
progression	O
was	O
concordant	O
with	O
our	O
previous	O
findings	O
regarding	O
GISTs	O
[	O
22	O
],	O
indicating	O
the	O
probable	O
random	O
occurrence	O
of	O
MTAP	B-GP
promoter	O
methylation	O
in	O
the	O
early	O
phase	O
of	O
myxofibrosarcoma	B-DS
tumorigenesis	O
.	O

However	O
,	O
MTAP	B-GP
homozygous	O
deletion	O
represents	O
a	O
relatively	O
late	O
genetic	O
event	O
in	O
the	O
tumor	B-DS
progression	O
,	O
which	O
may	O
confer	O
survival	O
advantage	O
to	O
aggressive	O
subclones	O
of	O
myxofibrosarcoma	B-DS
cells	O
and	O
thereby	O
culminate	O
in	O
negative	O
prognostic	O
impact	O
.	O

MTAP	B-GP
depletion	O
is	O
not	O
uncommon	O
in	O
human	B-OG
malignancies	O
and	O
is	O
primarily	O
attributable	O
to	O
homozygous	O
deletions	O
spanning	O
9p21	O
.	O
3	O
.	O

MTAP	B-GP
deficiency	O
may	O
occur	O
without	O
the	O
loss	O
of	O
adjoining	O
CDKN2A	B-GP
in	O
non	B-DS
-	I-DS
small	I-DS
cell	I-DS
lung	I-DS
cancers	I-DS
and	O
gliomas	B-DS
[	O
13	O
,	O
14	O
,	O
23	O
–	O
26	O
].	O

Instead	O
of	O
genomic	O
losses	O
,	O
promoter	O
hypermethylation	O
represents	O
the	O
preponderant	O
inactivating	O
mechanism	O
in	O
MTAP	B-GP
-	O
deficient	O
hepatocellular	B-DS
carcinomas	I-DS
[	O
21	O
].	O

Functionally	O
,	O
MTAP	B-GP
reexpression	O
in	O
MTAP	B-GP
-	O
deleted	O
breast	B-DS
cancer	I-DS
cells	O
may	O
inhibit	O
anchorage	O
-	O
independent	O
growth	O
and	O
in	O
vivo	O
tumorigenicity	O
[	O
9	O
].	O

Although	O
mice	B-OG
heterozygous	O
for	O
germline	O
MTAP	B-GP
mutations	O
did	O
not	O
fully	O
recapitulate	O
the	O
genetic	O
events	O
in	O
clinical	O
specimens	O
,	O
they	O
were	O
prone	O
to	O
developing	O
T	B-DS
-	I-DS
cell	I-DS
lymphomas	I-DS
;	O
however	O
,	O
homozygous	O
inactivation	O
was	O
embryonically	O
lethal	O
in	O
the	O
MTAP	B-GP
-	O
knockout	O
murine	O
model	O
[	O
11	O
].	O

Because	O
of	O
these	O
conflicting	O
findings	O
,	O
whether	O
the	O
loss	O
of	O
MTAP	B-GP
activity	O
is	O
pathogenically	O
relevant	O
remains	O
debated	O
[	O
9	O
,	O
11	O
,	O
12	O
].	O

Given	O
the	O
clinical	O
relevance	O
of	O
MTAP	B-GP
deficiency	O
in	O
myxofibrosarcomas	B-DS
,	O
we	O
characterized	O
the	O
biology	O
of	O
MTAP	B-GP
expression	O
to	O
clarify	O
its	O
functional	O
effects	O
on	O
cancer	B-DS
hallmark	O
-	O
related	O
phenotypes	O
.	O

The	O
antiproliferative	O
function	O
of	O
MTAP	B-GP
by	O
the	O
downregulation	O
of	O
cyclin	B-GP
D1	I-GP
was	O
validated	O
using	O
both	O
MTAP	B-GP
knockdown	O
in	O
MTAP	B-GP
-	O
expressing	O
NMFH	O
-	O
1	O
cells	O
and	O
MTAP	B-GP
-	O
reexpression	O
in	O
MTAP	B-GP
-	O
deficient	O
NMFH	O
-	O
2	O
cells	O
.	O

Regarding	O
the	O
latter	O
condition	O
,	O
the	O
growth	O
-	O
inhibiting	O
attribute	O
of	O
MTAP	B-GP
was	O
reinforced	O
by	O
the	O
reduced	O
proliferation	O
evidenced	O
in	O
the	O
ECIS	O
measurements	O
,	O
few	O
colonies	O
in	O
the	O
soft	O
-	O
agar	O
assays	O
,	O
and	O
low	O
-	O
grade	O
histology	O
of	O
the	O
corresponding	O
xenografted	O
specimens	O
exhibiting	O
an	O
underexpression	O
of	O
Ki	B-GP
-	I-GP
67	I-GP
and	O
cyclin	B-GP
D1	I-GP
.	O

We	O
also	O
corroborated	O
the	O
suppressive	O
role	O
of	O
MTAP	B-GP
in	O
metastasis	O
,	O
which	O
is	O
the	O
leading	O
cause	O
of	O
sarcoma	B-DS
-	O
associated	O
mortality	O
and	O
critically	O
involves	O
the	O
regulation	O
of	O
cell	O
motility	O
and	O
transgression	O
through	O
an	O
extracellular	O
matrix	O
[	O
2	O
,	O
27	O
,	O
28	O
].	O

In	O
MTAP	B-GP
-	O
reexpressing	O
NMFH	O
-	O
2	O
cells	O
,	O
delayed	O
closure	O
in	O
wound	O
-	O
healing	O
assays	O
and	O
decreased	O
invading	O
cells	O
through	O
matrix	O
-	O
coated	O
wells	O
were	O
measured	O
and	O
cross	O
-	O
validated	O
by	O
the	O
reverse	O
results	O
of	O
MTAP	B-GP
-	O
silenced	O
NMFH	O
-	O
1	O
cells	O
.	O

Clinically	O
,	O
the	O
independent	O
effect	O
of	O
MTAP	B-GP
deficiency	O
on	O
adverse	O
MFS	O
in	O
myxofibrosarcomas	B-DS
was	O
reflective	O
of	O
these	O
MTAP	B-GP
-	O
associated	O
antimigratory	O
and	O
antiinvasive	O
functions	O
.	O

In	O
MTAP	B-GP
-	O
reexpressing	O
and	O
shLacZ	O
-	O
transduced	O
myxofibrosarcoma	B-DS
cells	O
,	O
angiogenic	O
capability	O
was	O
significantly	O
impaired	O
,	O
as	O
indicated	O
by	O
reduced	O
levels	O
of	O
HUVEC	O
-	O
derived	O
tube	O
formation	O
.	O

Collectively	O
,	O
these	O
findings	O
corroborated	O
endogenous	O
MTAP	B-GP
as	O
a	O
functional	O
suppressor	O
that	O
governs	O
myxofibrosarcoma	B-DS
pathogenesis	O
by	O
inhibiting	O
tumor	B-DS
proliferation	O
,	O
metastasis	O
,	O
and	O
angiogenesis	O
.	O

In	O
the	O
luciferase	B-GP
reporter	O
assay	O
,	O
the	O
antiangiogenic	O
effect	O
of	O
MTAP	B-GP
was	O
determined	O
to	O
primarily	O
link	O
to	O
the	O
transcriptional	O
repression	O
of	O
MMP	B-GP
-	I-GP
9	I-GP
,	O
ultimately	O
attenuating	O
mRNA	O
and	O
protein	O
expression	O
in	O
the	O
myxofibrosarcoma	B-DS
cells	O
.	O

In	O
the	O
MTAP	B-GP
-	O
deficient	O
xenografts	O
and	O
myxofibrosarcoma	B-DS
specimens	O
,	O
MMP	B-GP
-	I-GP
9	I-GP
overexpression	O
was	O
present	O
in	O
the	O
tumor	B-DS
cells	O
and	O
extracellular	O
stroma	O
and	O
associated	O
with	O
increased	O
microvessel	O
density	O
.	O

These	O
exemplified	O
the	O
oncogenic	O
role	O
of	O
MMP	B-GP
-	I-GP
9	I-GP
in	O
myxofibrosarcoma	B-DS
pathogenesis	O
and	O
corresponded	O
with	O
previous	O
reports	O
on	O
its	O
associations	O
with	O
aggressiveness	O
in	O
various	O
cancer	B-DS
types	O
[	O
15	O
,	O
28	O
].	O

Kiroviski	O
reported	O
that	O
MTAP	B-GP
knockdown	O
upregulated	O
MMP	B-GP
-	I-GP
9	I-GP
expression	O
through	O
the	O
accumulation	O
of	O
5	O
′-	O
deoxy	O
-	O
5	O
′-	O
methylthioadenosine	O
in	O
hepatocellular	B-DS
carcinomas	I-DS
[	O
29	O
].	O

However	O
,	O
they	O
neither	O
elucidated	O
the	O
mechanistic	O
link	O
between	O
MTAP	B-GP
deficiency	O
and	O
MMP	B-GP
-	I-GP
9	I-GP
nor	O
characterized	O
the	O
functional	O
effect	O
of	O
this	O
perturbed	O
regulatory	O
chain	O
on	O
angiogenesis	O
and	O
metastasis	O
.	O

Because	O
MTAP	B-GP
is	O
not	O
a	O
transcriptional	B-GP
factor	I-GP
,	O
it	O
is	O
conceivable	O
to	O
hypothesize	O
that	O
MTAP	B-GP
deficiency	O
indirectly	O
transactivates	O
an	O
MMP	B-GP
-	I-GP
9	I-GP
promoter	O
,	O
causing	O
resultant	O
aggressive	O
phenotypes	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
the	O
antiangiogenic	O
function	O
of	O
ASS1	B-GP
,	O
a	O
rate	O
-	O
limiting	O
enzyme	O
converting	O
citrulline	O
into	O
arginine	O
in	O
the	O
urea	O
cycle	O
,	O
was	O
also	O
attributable	O
to	O
the	O
inhibition	O
of	O
ASS1	B-GP
on	O
MMP	B-GP
-	I-GP
9	I-GP
expression	O
in	O
myxofibrosarcomas	B-DS
[	O
15	O
].	O

Evidently	O
,	O
aberrant	O
losses	O
of	O
both	O
MTAP	B-GP
in	O
methionine	O
salvage	O
and	O
ASS1	B-GP
in	O
arginine	O
metabolism	O
may	O
upregulate	O
ornithine	B-GP
decarboxylase	I-GP
(	O
ODC	B-GP
)	O
and	O
subsequently	O
induce	O
overproduction	O
of	O
putrescine	O
and	O
other	O
polyamines	O
[	O
17	O
,	O
30	O
,	O
31	O
].	O

This	O
alteration	O
is	O
one	O
of	O
the	O
first	O
processes	O
involved	O
in	O
proliferating	O
cells	O
preceding	O
nucleic	O
acid	O
and	O
protein	O
syntheses	O
and	O
recently	O
has	O
been	O
reported	O
to	O
promote	O
tumor	B-DS
development	O
and	O
progression	O
involving	O
multiple	O
cancer	B-DS
hallmarks	O
[	O
16	O
,	O
30	O
].	O

For	O
instance	O
,	O
ODC	B-GP
transformants	O
were	O
reported	O
to	O
increase	O
secreted	O
MMP	B-GP
-	I-GP
2	I-GP
in	O
vitro	O
to	O
enhance	O
matrix	O
degradation	O
[	O
30	O
].	O

Analogously	O
,	O
MMP	B-GP
-	I-GP
9	I-GP
overexpression	O
in	O
the	O
ASS1	B-GP
-	O
deficient	O
and	O
MTAP	B-GP
-	O
deficient	O
myxofibrosarcomas	B-DS
is	O
likely	O
mediated	O
by	O
overexpressed	O
ODC	B-GP
,	O
which	O
converges	O
growth	O
-	O
promoting	O
signals	O
to	O
orchestrate	O
transcriptional	O
regulation	O
.	O

The	O
disabled	O
methionine	O
salvage	O
in	O
MTAP	B-GP
-	O
inactivated	O
myxofibrosarcomas	B-DS
renders	O
this	O
aggressive	O
tumor	B-DS
subset	O
a	O
tumor	B-DS
-	O
specific	O
metabolic	O
feature	O
for	O
use	O
in	O
L	O
-	O
alanosine	O
therapy	O
,	O
which	O
targets	O
adenylosuccinate	B-GP
synthetase	I-GP
to	O
abolish	O
de	O
novo	O
AMP	O
synthesis	O
from	O
IMP	O
[	O
13	O
,	O
14	O
,	O
30	O
].	O
In	O
vitro	O
and	O
in	O
vivo	O
,	O
the	O
growth	O
inhibition	O
of	O
MTAP	B-GP
-	O
deficient	O
tumors	B-DS
by	O
L	O
-	O
alanosine	O
was	O
partially	O
ascribed	O
to	O
the	O
induction	O
of	O
apoptosis	O
,	O
which	O
was	O
evidenced	O
by	O
increased	O
Annexin	B-GP
-	I-GP
V	I-GP
and	O
TUNEL	B-GP
labeling	O
in	O
myxofibrosarcomas	B-DS
and	O
reported	O
to	O
be	O
mitochondria	O
-	O
dependent	O
in	O
mantle	B-DS
cell	I-DS
lymphomas	I-DS
[	O
24	O
].	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
myxofibrosarcomas	B-DS
fundamentally	O
depended	O
on	O
MTAP	B-GP
deficiency	O
regarding	O
their	O
susceptibility	O
to	O
L	O
-	O
alanosine	O
,	O
which	O
effectively	O
inhibited	O
the	O
MTAP	B-GP
-	O
deficient	O
cell	O
lines	O
and	O
derived	O
xenografts	O
and	O
was	O
well	O
-	O
tolerated	O
by	O
the	O
mice	B-OG
.	O

Since	O
several	O
antimetabolites	O
targeting	O
purine	O
synthesis	O
are	O
available	O
and	O
additional	O
drugs	O
are	O
in	O
development	O
[	O
32	O
–	O
34	O
],	O
the	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
MTAP	B-GP
-	O
deficient	O
myxofibrosarcomas	B-DS
may	O
benefit	O
from	O
the	O
chemoselective	O
targeting	O
of	O
the	O
defects	O
in	O
methionine	O
-	O
adenine	O
recycling	O
and	O
AMP	O
synthesis	O
.	O

In	O
summary	O
,	O
MTAP	B-GP
deficiency	O
in	O
myxofibrosarcomas	B-DS
,	O
and	O
particularly	O
that	O
caused	O
by	O
homozygous	O
deletion	O
,	O
negatively	O
affects	O
prognosis	O
.	O
In	O
vitro	O
and	O
in	O
vivo	O
,	O
MTAP	B-GP
may	O
act	O
as	O
a	O
tumor	B-DS
suppressor	O
,	O
serving	O
antiangiogenic	O
,	O
antiproliferative	O
,	O
and	O
antimigratory	O
or	O
antiinvasive	O
functions	O
,	O
and	O
its	O
deficiency	O
represents	O
a	O
potential	O
therapeutic	O
target	O
of	O
myxofibrosarcomas	B-DS
.	O

MATERIALS	O
AND	O
METHODS	O

Analysis	O
of	O
aCGH	O

Twelve	O
fresh	O
tumor	B-DS
specimens	O
and	O
3	O
myxofibrosarcoma	B-DS
cell	O
lines	O
(	O
OH931	O
,	O
NMFH	O
-	O
1	O
,	O
and	O
NMFH	O
-	O
2	O
)	O
underwent	O
oligonucleotide	O
-	O
based	O
aCGH	O
profiling	O
(	O
NimbleGen	O
),	O
as	O
previously	O
detailed	O
[	O
7	O
,	O
15	O
].	O

The	O
raw	O
data	O
from	O
the	O
aCGH	O
profiling	O
were	O
log2	O
-	O
transformed	O
and	O
output	O
into	O
Nexus	O
software	O
(	O
BioDiscovery	O
).	O

To	O
delineate	O
the	O
breakpoints	O
in	O
the	O
genome	O
-	O
wide	O
array	O
probes	O
,	O
the	O
gains	O
and	O
losses	O
in	O
the	O
critical	O
regions	O
of	O
the	O
CNAs	O
were	O
defined	O
as	O
log2	O
ratios	O
of	O
≥	O
+	O
0	O
.	O
20	O
and	O
≤	O
−	O
0	O
.	O
20	O
,	O
respectively	O
.	O

The	O
amplification	O
and	O
homozygous	O
deletion	O
were	O
defined	O
as	O
log2	O
ratios	O
of	O
≥	O
+	O
0	O
.	O
50	O
or	O
≤	O
−	O
0	O
.	O
50	O
,	O
respectively	O
.	O

To	O
unravel	O
causal	O
genes	O
exhibiting	O
copy	O
number	O
-	O
driven	O
deregulated	O
expression	O
,	O
the	O
common	O
regions	O
of	O
alteration	O
were	O
filtered	O
to	O
identify	O
consecutive	O
makers	O
,	O
and	O
their	O
proportions	O
were	O
^	O
20	O
%	O
in	O
the	O
tumor	B-DS
and	O
cell	O
line	O
samples	O
analyzed	O
.	O

Tumor	B-DS
materials	O

An	O
institutional	O
review	O
board	O
(	O
97	O
-	O
2190A3	O
)	O
approved	O
the	O
retrieval	O
of	O
myxofibrosarcomas	B-DS
resected	O
with	O
curative	O
intent	O
.	O

Those	O
undergoing	O
neoadjuvant	O
radiation	O
,	O
chemotherapy	O
or	O
aCGH	O
profiling	O
were	O
excluded	O
.	O

Table	O
1	O
lists	O
the	O
87	O
independent	O
primary	O
formalin	O
-	O
fixed	O
myxofibrosarcomas	B-DS
successfully	O
analyzed	O
for	O
MTAP	B-GP
gene	O
dosage	O
,	O
promoter	O
methylation	O
,	O
and	O
immunoexpression	O
.	O

Immunohistochemistry	O

Tissue	O
microarray	O
sections	O
were	O
antigen	O
-	O
retrieved	O
,	O
incubated	O
with	O
antibodies	O
targeting	O
MTAP	B-GP
(	O
1	O
:	O
100	O
,	O
Proteintech	O
),	O
Ki	B-GP
-	I-GP
67	I-GP
(	O
1	O
:	O
200	O
,	O
abcam	O
),	O
MMP	B-GP
-	I-GP
9	I-GP
(	O
1	O
:	O
50	O
,	O
Epitomics	O
),	O
and	O
CD31	B-GP
(	O
1	O
:	O
50	O
,	O
BD	O
Pharmingen	O
),	O
and	O
detected	O
using	O
the	O
ChemMate	O
EnVision	O
kit	O
.	O

The	O
cutoff	O
value	O
of	O
<	O
10	O
%	O
cytoplasmic	O
reactivity	O
to	O
define	O
aberrant	O
MTAP	B-GP
loss	O
was	O
previously	O
described	O
[	O
22	O
].	O

The	O
scoring	O
criteria	O
of	O
determining	O
the	O
levels	O
of	O
intratumoral	O
microvessel	O
density	O
[	O
18	O
]	O
and	O
MMP	B-GP
-	I-GP
9	I-GP
expression	O
by	O
H	O
-	O
score	O
method	O
[	O
19	O
]	O
were	O
as	O
previously	O
reported	O
.	O

Whole	O
sections	O
of	O
xenografted	O
specimens	O
were	O
stained	O
with	O
MTAP	B-GP
(	O
1	O
:	O
50	O
,	O
Proteintech	O
),	O
cyclin	B-GP
D1	I-GP
(	O
1	O
:	O
100	O
,	O
Epitomics	O
),	O
cyclin	B-GP
E	I-GP
(	O
1	O
:	O
20	O
,	O
Abcam	O
),	O
Ki	B-GP
-	I-GP
67	I-GP
(	O
1	O
:	O
200	O
,	O
abcam	O
),	O
MMP	B-GP
-	I-GP
9	I-GP
(	O
1	O
:	O
50	O
,	O
Epitomics	O
),	O
CD31	B-GP
(	O
1	O
:	O
50	O
,	O
BD	O
Pharmingen	O
),	O
and	O
TUNEL	B-GP
(	O
Roche	O
)	O
for	O
labeling	O
apoptotic	O
cells	O
.	O

MTAP	B-GP
dosage	O
quantification	O

As	O
described	O
in	O
Supplementary	O
Method	O
-	O
S1	O
,	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
performed	O
on	O
MTAP	B-GP
exon	O
8	O
in	O
duplicate	O
for	O
each	O
case	O
to	O
detect	O
the	O
MTAP	B-GP
gene	O
dosage	O
.	O
PIK3R1	B-GP
(	O
5q13	O
.	O
1	O
)	O
was	O
the	O
reference	O
gene	O
that	O
exhibited	O
no	O
detectable	O
CNAs	O
in	O
the	O
aCGH	O
.	O

Standard	O
curves	O
were	O
constructed	O
using	O
serial	O
dilutions	O
of	O
human	B-OG
genomic	O
DNA	O
(	O
Clontech	O
).	O

For	O
each	O
specimen	O
,	O
approximately	O
3000	O
tumor	B-DS
cells	O
were	O
microdissected	O
using	O
the	O
Veritas	O
LCM	O
machine	O
(	O
Arcturus	O
)	O
to	O
extract	O
genomic	O
DNA	O
.	O

The	O
MTAP	B-GP
/	O
PIK3R1	B-GP
ratio	O
<	O
0	O
.	O
2	O
was	O
considered	O
a	O
homozygous	O
deletion	O
,	O
assuming	O
that	O
the	O
normal	O
tissue	O
contamination	O
and	O
intratumoral	O
heterogeneity	O
accounted	O
for	O
<	O
20	O
%	O
of	O
the	O
experimental	O
deviation	O
.	O

Regarding	O
the	O
3	O
myxofibrosarcoma	B-DS
cell	O
lines	O
,	O
homozygous	O
deletion	O
was	O
determined	O
when	O
no	O
MTAP	B-GP
gene	O
copy	O
was	O
detected	O
but	O
PIK3R1	B-GP
was	O
amplifiable	O
,	O
i	O
.	O
e	O
.	O
the	O
MTAP	B-GP
/	O
PIK3R1	B-GP
ratio	O
approximating	O
zero	O
.	O

Methylation	O
-	O
specific	O
PCR	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
formalin	O
-	O
fixed	O
tissue	O
,	O
bisulfite	O
-	O
converted	O
,	O
and	O
PCR	O
-	O
amplified	O
with	O
primers	O
targeting	O
methylated	O
and	O
unmethylated	O
promoters	O
of	O
MTAP	B-GP
gene	O
,	O
as	O
previously	O
described	O
[	O
22	O
].	O

Cell	O
culture	O
,	O
transfection	O
,	O
and	O
RNA	O
interference	O

The	O
culture	O
conditions	O
of	O
the	O
OH931	O
,	O
NMFH	O
-	O
1	O
,	O
and	O
NMFH	O
-	O
2	O
myxofibrosarcoma	B-DS
cell	O
lines	O
,	O
CCD966SK	O
dermal	O
fibroblasts	O
,	O
and	O
human	B-OG
umbilical	O
venous	O
endothelial	O
cells	O
(	O
HUVECs	O
,	O
H	O
-	O
UV001	O
)	O
were	O
previously	O
described	O
[	O
15	O
]	O
and	O
were	O
authenticated	O
using	O
short	O
tandem	O
-	O
repeat	O
fingerprinting	O
in	O
December	O
,	O
2013	O
.	O

Regarding	O
the	O
MTAP	B-GP
reexpression	O
in	O
MTAP	B-GP
-	O
deleted	O
OH931	O
and	O
NMFH	O
-	O
2	O
cells	O
,	O
a	O
full	O
-	O
length	O
pMTAP	O
-	O
DDK	O
-	O
Myc	B-GP
expression	O
plasmid	O
and	O
empty	O
pCMV6	O
vector	O
were	O
purchased	O
from	O
Origene	O
and	O
validated	O
using	O
sequencing	O
.	O

In	O
a	O
24	O
-	O
well	O
plate	O
,	O
105	O
cells	O
from	O
OH931	O
or	O
NMFH	O
-	O
2	O
myxofibrosarcoma	B-DS
cell	O
lines	O
were	O
seeded	O
and	O
incubated	O
with	O
lipofectamine	O
2000	O
(	O
Invitrogene	O
)	O
for	O
4	O
h	O
at	O
37	O
°	O
C	O
to	O
transfect	O
various	O
plasmids	O
(	O
1	O
.	O
5	O
μg	O
),	O
then	O
cultured	O
for	O
a	O
further	O
24	O
h	O
at	O
37	O
°	O
C	O
,	O
and	O
lysed	O
with	O
Passive	O
Lysis	O
Buffer	O
(	O
Promega	O
).	O

Cells	O
stably	O
expressing	O
MTAP	B-GP
or	O
DDK	O
-	O
Myc	B-GP
tags	O
alone	O
were	O
selected	O
using	O
neomycin	O
.	O

The	O
transfected	O
cells	O
were	O
analyzed	O
for	O
exogenous	O
MTAP	B-GP
expression	O
using	O
western	O
blotting	O
.	O

To	O
evaluate	O
the	O
MMP	B-GP
-	I-GP
9	I-GP
promoter	O
activity	O
,	O
an	O
empty	O
pGL	O
vector	O
and	O
pG	O
-	O
MMP	B-GP
-	I-GP
9	I-GP
-	O
promoter	O
were	O
cotransfected	O
with	O
a	O
pCMV6	O
control	O
or	O
a	O
pMTAP	O
-	O
DDK	O
-	O
Myc	B-GP
vector	O
into	O
myxofibrosarcoma	B-DS
cells	O
[	O
35	O
].	O

After	O
48	O
h	O
,	O
the	O
cells	O
underwent	O
luciferase	B-GP
assays	O
by	O
using	O
a	O
dual	O
luciferase	B-GP
assay	O
kit	O
(	O
Promega	O
)	O
and	O
normalized	O
for	O
the	O
transfection	O
efficiency	O
of	O
pRL	O
vector	O
.	O

To	O
silence	O
the	O
endogenous	O
MTAP	B-GP
expression	O
in	O
NMFH	O
-	O
1	O
cells	O
,	O
lentiviral	O
vectors	O
were	O
obtained	O
from	O
the	O
Taiwan	O
National	O
RNAi	O
Core	O
Facility	O
.	O

Viruses	B-OG
were	O
produced	O
by	O
transfecting	O
HEK293	O
cells	O
with	O
the	O
control	O
pLKO	O
.	O
1	O
-	O
shLacZ	O
(	O
TRCN0000072223	O
:	O
5	O
′-	O
TGTTCGCATTAT	O
CCGAACCAT	O
-	O
3	O
′)	O
and	O
pLKO	O
.	O
1	O
-	O
shMTAP	O
(	O
TRCN0000005883	O
:	O
5	O
′-	O
CCTGAATGATTTAGACAAC	O
-	O
3	O
′	O
and	O
TRCN0000005885	O
:	O
5	O
′-	O
CCTTCTATGATGGAAGTCA	O
-	O
3	O
′)	O
using	O
Lipofectamine	O
2000	O
.	O

For	O
viral	B-DS
infection	I-DS
,	O
3	O
×	O
106	O
NMFH	O
-	O
1	O
cells	O
were	O
incubated	O
with	O
8	O
mL	O
of	O
lentivirus	B-OG
in	O
the	O
presence	O
of	O
polybrene	O
,	O
followed	O
by	O
puromycin	O
selection	O
to	O
produce	O
stable	O
clones	O
of	O
lentivirus	B-OG
-	O
transduced	O
cells	O
.	O

Quantification	O
of	O
transcripts	O
of	O
MTAP	B-GP
and	O
angiogenesis	O
-	O
associated	O
genes	O

As	O
detailed	O
in	O
Method	O
-	O
S2	O
,	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
performed	O
using	O
the	O
ABI	O
StepOnePlus	O
™	O
System	O
to	O
measure	O
MTAP	B-GP
mRNA	O
abundance	O
in	O
all	O
myxofibrosarcoma	B-DS
cell	O
lines	O
.	O

To	O
explore	O
antiangiogenic	O
mediators	O
of	O
MTAP	B-GP
,	O
an	O
RT	O
-	O
PCR	O
expression	O
array	O
(	O
PAHS	O
-	O
024	O
,	O
SABioscience	O
)	O
was	O
profiled	O
for	O
NMFH	O
-	O
2	O
cells	O
.	O

Those	O
genes	O
differentially	O
expressed	O
between	O
MTAP	B-GP
-	O
reexpressing	O
and	O
empty	O
conditions	O
were	O
identified	O
based	O
on	O
P	O
<	O
0	O
.	O
001	O
,	O
>	O
5	O
-	O
fold	O
changes	O
,	O
and	O
Ct	O
values	O
%	O
30	O
for	O
both	O
tested	O
and	O
housekeeping	O
genes	O
.	O

These	O
candidates	O
were	O
further	O
screened	O
in	O
all	O
myxofibrosarcoma	B-DS
cell	O
lines	O
using	O
western	O
blots	O
to	O
assay	O
molecules	O
exhibiting	O
corresponding	O
protein	O
alterations	O
under	O
varying	O
MTAP	B-GP
reexpression	O
or	O
knockdown	O
experiments	O
.	O

Western	O
blots	O

To	O
visualize	O
protein	O
expression	O
alterations	O
,	O
Method	O
-	O
S3	O
details	O
the	O
western	O
blots	O
,	O
sources	O
of	O
primary	O
antibodies	O
against	O
MTAP	B-GP
,	O
G1	O
-	O
and	O
G1	O
/	O
S	O
transition	O
-	O
associated	O
cell	O
cycle	O
regulators	O
,	O
and	O
RT	O
-	O
PCR	O
expression	O
array	O
-	O
selected	O
angiogenesis	O
-	O
associated	O
mediators	O
.	O

The	O
proteins	O
consistently	O
downregulated	O
or	O
upregulated	O
by	O
MTAP	B-GP
reexpression	O
in	O
MTAP	B-GP
-	O
deficient	O
OH931	O
and	O
NMFH	O
-	O
2	O
cells	O
were	O
reappraised	O
in	O
endogenously	O
MTAP	B-GP
-	O
expressing	O
NMFH	O
-	O
1	O
cells	O
transduced	O
with	O
shMTAP	O
or	O
shLacZ	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O

After	O
the	O
aforementioned	O
cross	O
-	O
validations	O
were	O
conducted	O
,	O
the	O
identified	O
molecule	O
(	O
s	O
)	O
exhibiting	O
the	O
same	O
trend	O
in	O
changes	O
in	O
protein	O
abundance	O
,	O
as	O
modulated	O
by	O
the	O
MTAP	B-GP
expression	O
level	O
,	O
underwent	O
ELISA	O
to	O
quantify	O
their	O
concentration	O
in	O
corresponding	O
conditioned	O
media	O
,	O
as	O
detailed	O
in	O
Method	O
-	O
S4	O
.	O

Pharmacological	O
assessment	O

Parent	O
OH931	O
,	O
NMFH	O
-	O
2	O
,	O
and	O
NMFH	O
-	O
1	O
cells	O
,	O
as	O
well	O
as	O
the	O
MTAP	B-GP
-	O
or	O
empty	O
vector	O
-	O
transfected	O
OH931	O
and	O
NMFH	O
-	O
2	O
cells	O
,	O
were	O
treated	O
with	O
a	O
vehicle	O
control	O
using	O
0	O
.	O
9	O
%	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
or	O
L	O
-	O
alanosine	O
(	O
Santa	O
Cruz	O
Biotech	O
)	O
at	O
indicated	O
doses	O
for	O
72	O
h	O
.	O

Functional	O
assays	O

To	O
elucidate	O
the	O
functional	O
alterations	O
associated	O
with	O
MTAP	B-GP
reexpression	O
,	O
MTAP	B-GP
knockdown	O
,	O
and	O
L	O
-	O
alanosine	O
treatment	O
,	O
various	O
cancer	B-DS
phenotypes	O
were	O
evaluated	O
using	O
cell	O
viability	O
,	O
bromodeoxyuridine	O
(	O
BrdU	O
),	O
electric	O
cell	O
-	O
substrate	O
impedance	O
sensing	O
(	O
ECIS	O
),	O
cell	O
cycle	O
kinetics	O
,	O
soft	O
-	O
agar	O
,	O
HUVEC	O
tube	O
formation	O
,	O
and	O
wound	O
-	O
healing	O
,	O
invasion	O
,	O
and	O
apoptosis	O
assays	O
in	O
Methods	O
-	O
S5	O
-	O
S11	O
.	O

Animal	B-OG
xenografts	O

The	O
animal	B-OG
use	O
committee	O
approved	O
the	O
protocol	O
103101401	O
.	O

To	O
elucidate	O
the	O
in	O
vivo	O
function	O
of	O
MTAP	B-GP
reexpression	O
,	O
4	O
×	O
106	O
NMFH	O
-	O
2	O
myxofibrosarcoma	B-DS
cells	O
transfected	O
with	O
the	O
MTAP	B-GP
-	O
expressing	O
plasmid	O
or	O
empty	O
vector	O
(	O
n	O
=	O
8	O
each	O
)	O
were	O
inoculated	O
into	O
the	O
flanks	O
of	O
16	O
severe	O
combined	O
immunodeficient	O
(	O
SCID	O
)	O
mice	B-OG
(	O
BioLasco	O
)	O
and	O
allowed	O
to	O
grow	O
until	O
30	O
d	O
after	O
cell	O
implantation	O
.	O

To	O
analyze	O
the	O
in	O
vivo	O
therapeutic	O
effect	O
of	O
L	O
-	O
alanosine	O
,	O
4	O
×	O
106	O
parent	O
NMFH	O
-	O
2	O
cells	O
were	O
inoculated	O
into	O
24	O
SCID	O
mice	B-OG
,	O
which	O
were	O
allowed	O
to	O
grow	O
until	O
10	O
d	O
postinjection	O
(	O
Day	O
0	O
),	O
and	O
then	O
randomized	O
into	O
3	O
groups	O
(	O
n	O
=	O
8	O
each	O
)	O
receiving	O
25	O
μM	O
or	O
50	O
μM	O
of	O
L	O
-	O
alanosine	O
,	O
or	O
PBS	O
.	O

The	O
treatment	O
was	O
continued	O
for	O
6	O
wk	O
and	O
the	O
mice	B-OG
were	O
euthanized	O
42	O
d	O
posttreatment	O
.	O

The	O
tumor	B-DS
volume	O
was	O
calculated	O
using	O
the	O
formula	O
:	O
V	O
=	O
π	O
/	O
6	O
×	O
length	O
(	O
mm	O
)	O
×	O
width	O
(	O
mm	O
)	O
2	O
.	O

Statistical	O
analysis	O

The	O
associations	O
and	O
comparisons	O
among	O
various	O
parameters	O
were	O
evaluated	O
using	O
chi	O
-	O
square	O
,	O
Student	O
t	O
,	O
or	O
Mann	O
-	O
Whitney	O
U	O
test	O
as	O
appropriate	O
to	O
assess	O
the	O
MTAP	B-GP
gene	O
status	O
and	O
MTAP	B-GP
immunoexpression	O
.	O

Follow	O
-	O
up	O
data	O
were	O
available	O
for	O
83	O
patients	O
,	O
and	O
the	O
median	O
follow	O
-	O
up	O
time	O
was	O
30	O
.	O
6	O
mo	O
.	O

The	O
endpoints	O
were	O
metastasis	O
-	O
free	O
survival	O
(	O
MFS	O
)	O
and	O
disease	O
-	O
specific	O
survival	O
(	O
DSS	O
).	O

Univariate	O
survival	O
analyses	O
were	O
compared	O
using	O
a	O
log	O
-	O
rank	O
test	O
.	O

A	O
multivariate	O
model	O
was	O
performed	O
using	O
a	O
Cox	O
regression	O
,	O
including	O
parameters	O
with	O
univariate	O
P	O
<	O
0	O
.	O
05	O
.	O

For	O
cell	O
line	O
and	O
xenograft	O
samples	O
,	O
a	O
Student	O
'	O
s	O
t	O
-	O
test	O
was	O
used	O
to	O
analyze	O
the	O
functional	O
and	O
pharmacological	O
assays	O
.	O

SUPPLEMENTARY	O
METHODS	O
,	O
TABLES	O
AND	O
FIGURES	O

Disclosure	O

The	O
authors	O
declare	O
no	O
conflicts	O
of	O
interest	O
.	O

